- Home
- ASBP vs NRSN Comparison
ASBP vs NRSN Comparison
Compare ASBP & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | NRSN |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 14.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASBP | NRSN |
|---|---|---|
| Price | $9.20 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 33.5K | ★ 348.2K |
| Earning Date | 04-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.25 |
| 52 Week High | $9.50 | $7.50 |
Technical Indicators
Market Signals| Indicator | ASBP | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 63.33 |
| Support Level | $7.80 | $0.63 |
| Resistance Level | $9.50 | $7.50 |
| Average True Range (ATR) | 0.65 | 0.74 |
| MACD | -0.08 | 0.17 |
| Stochastic Oscillator | 69.70 | 73.50 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.